🚀 VC round data is live in beta, check it out!
Acarix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Acarix and similar public comparables like Ortoma, Diagnostic Medical Systems, Mentice, Nortech Systems and more.
Acarix Overview
About Acarix
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics.
Founded
2009
HQ
Employees
8
Website
Sectors
Financials (LTM)
EV
$35M
Acarix Financials
Acarix reported last 12-month revenue of $1M and negative EBITDA of ($5M).
In the same LTM period, Acarix generated $1M in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Acarix P&L
In the most recent fiscal year, Acarix reported revenue of $832K and EBITDA of ($5M).
Acarix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $832K | XXX | XXX | XXX |
| Gross Profit | $1M | XXX | $681K | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | (369%) | XXX | (585%) | XXX | XXX | XXX |
| EBIT Margin | (401%) | XXX | (630%) | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (401%) | XXX | (631%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Acarix Stock Performance
Acarix has current market cap of $38M, and enterprise value of $35M.
Market Cap Evolution
Acarix's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35M | $38M | 0.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAcarix Valuation Multiples
Acarix trades at 28.2x EV/Revenue multiple, and (7.6x) EV/EBITDA.
EV / Revenue (LTM)
Acarix Financial Valuation Multiples
As of April 19, 2026, Acarix has market cap of $38M and EV of $35M.
Equity research analysts estimate Acarix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acarix has a P/E ratio of (7.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV/Revenue | 28.2x | XXX | 41.8x | XXX | XXX | XXX |
| EV/EBITDA | (7.6x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/EBIT | (7.1x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 33.0x | XXX | 51.1x | XXX | XXX | XXX |
| P/E | (7.7x) | XXX | (7.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Acarix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Acarix Margins & Growth Rates
Acarix's revenue in the last 12 month grew by 208%.
Acarix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Acarix's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Acarix's rule of X is 265% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Acarix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 208% | XXX | 161% | XXX | XXX | XXX |
| EBITDA Margin | (369%) | XXX | (585%) | XXX | XXX | XXX |
| EBITDA Growth | (50%) | XXX | (28%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 10% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 265% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 518% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 132% | XXX | 200% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 712% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Acarix Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Acarix | XXX | XXX | XXX | XXX | XXX | XXX |
| Ortoma | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnostic Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Mentice | XXX | XXX | XXX | XXX | XXX | XXX |
| Nortech Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Mauna Kea Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acarix M&A Activity
Acarix acquired XXX companies to date.
Last acquisition by Acarix was on XXXXXXXX, XXXXX. Acarix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Acarix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAcarix Investment Activity
Acarix invested in XXX companies to date.
Acarix made its latest investment on XXXXXXXX, XXXXX. Acarix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Acarix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Acarix
| When was Acarix founded? | Acarix was founded in 2009. |
| Where is Acarix headquartered? | Acarix is headquartered in Sweden. |
| How many employees does Acarix have? | As of today, Acarix has over 8 employees. |
| Is Acarix publicly listed? | Yes, Acarix is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Acarix? | Acarix trades under ACARIX ticker. |
| When did Acarix go public? | Acarix went public in 2016. |
| Who are competitors of Acarix? | Acarix main competitors are Ortoma, Diagnostic Medical Systems, Mentice, Nortech Systems. |
| What is the current market cap of Acarix? | Acarix's current market cap is $38M. |
| What is the current revenue of Acarix? | Acarix's last 12 months revenue is $1M. |
| What is the current revenue growth of Acarix? | Acarix revenue growth (NTM/LTM) is 208%. |
| What is the current EV/Revenue multiple of Acarix? | Current revenue multiple of Acarix is 28.2x. |
| Is Acarix profitable? | No, Acarix is not profitable. |
| What is the current EBITDA of Acarix? | Acarix has negative EBITDA and is not profitable. |
| What is Acarix's EBITDA margin? | Acarix's last 12 months EBITDA margin is (369%). |
| What is the current EV/EBITDA multiple of Acarix? | Current EBITDA multiple of Acarix is (7.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.